Progress in the treatment of acquired aplastic anemia in children
10.3760/cma.j.issn.1673-4408.2022.12.003
- VernacularTitle:儿童获得性再生障碍性贫血的治疗进展
- Author:
Zhongjian WANG
1
;
Yining QIU
;
Runming JIN
Author Information
1. 华中科技大学同济医学院附属协和医院儿科，武汉 430022
- Keywords:
Children;
Aplastic anemia;
Hematopoietic stem cell transplantation;
Eltrombopag;
Tacrolimus
- From:
International Journal of Pediatrics
2022;49(12):804-808
- CountryChina
- Language:Chinese
-
Abstract:
Aplastic anemia(AA) is a bone marrow failure disease in which peripheral blood is reduced in two or three lines.Clinically, patients are at high risk of bleeding and infection, which may endanger their lives in serious cases.Due to the great differences in economic conditions, medical conditions and AA epidemiology in various regions around the world, there are many treatment methods for newly diagnosed, refractory / relapsed AA patients and their curative effects are different.Haploidentical hematopoietic stem cell transplantation, eltrombopag and tacrolimus are the research focuses in recent years.To facilitate clinicians to choose more appropriate treatments, this paper reviews the progress of hematopoietic stem cell transplantation therapy and non-transplantation therapy in patients with AA.
